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OBJECTIVEdThe epidemic of type 2 diabetes (T2DM) threatens to become the major public
health problem of this century. However, a comprehensive comparison of the long-term effects of
medications to treat T2DM has not been conducted. GRADE, a pragmatic, unmasked clinical
trial, aims to compare commonly used diabetes medications, when combined with metformin,
on glycemia-lowering effectiveness and patient-centered outcomes.
RESEARCH DESIGN AND METHODSdGRADE was designed with support from a
U34 planning grant from the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK). The consensus protocol was approved by NIDDK and the GRADE Research Group.
Eligibility criteria for the 5,000 metformin-treated subjects include,5 years’ diabetes duration,
$30 years of age at time of diagnosis, and baseline hemoglobin A1c (A1C) of 6.8–8.5% (51–69
mmol/mol). Medications representing four classes (sulfonylureas, dipeptidyl peptidase 4 inhib-
itors, glucagon-like peptide 1 receptor agonists, and insulin) will be randomly assigned and added
to metformin (minimum–maximum 1,000–2,000 mg/day). The primary metabolic outcome is
the time to primary failure defined as an A1C $7% (53 mmol/mol), subsequently confirmed,
over an anticipated mean observation period of 4.8 years (range 4–7 years). Other long-term met-
abolic outcomes include the need for the addition of basal insulin after a confirmed A1C .7.5%
(58 mmol/mol) and, ultimately, the need to implement an intensive basal/bolus insulin regimen.
The four drugs will also be compared with respect to selected microvascular complications, cardio-
vascular disease risk factors, adverse effects, tolerability, quality of life, and cost-effectiveness.
CONCLUSIONSdGRADE will compare the long-term effectiveness of major glycemia-
loweringmedications and provide guidance to clinicians about themost appropriate medications
to treat T2DM. GRADE begins recruitment at 37 centers in the U.S. in 2013.
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The epidemic of type 2 diabetes(T2DM) that has affected the U.S.and other populations, is associated
with the relentless increase in obesity, and
threatens to become the major public
health problem of this century, affecting
up to one in three Americans if current
trends continue (1). The most recent
estimate of T2DM prevalence in the U.S.
is .24 million people, with an incidence
of 1.9 million new cases per year (1). Ma-
jor human and economic costs associated
with the epidemic are related to the de-
velopment of long-term complications,
including retinopathy, nephropathy, and
neuropathy, that cause more cases of
blindness, renal failure, and amputations
than any other disease (2). Cardiovascular
disease (CVD) is increased by two- to five-
fold in diabetes and is the leading cause of
death (3). The 2012 estimated annual cost
of diabetes in the U.S. was $245 billion,
with the greatest cost related to its chronic
complications (4). In 2007, the annual
expenditure for glucose-lowering drugs
in the U.S. was $13 billion, almost dou-
bling since 2001 (5). The estimate in 2012
was .$18 billion (4).
There are several reasons for guarded
optimism in the setting of this ongoing
epidemic. First, clinical trials have dem-
onstrated effective means of delaying or
preventing the development of diabetes
(6–8). If these interventions were imple-
mented successfully, they could decrease
the annual incidence of diabetes substan-
tially. Second, high-quality clinical trials
have shown that lowering A1C to ;7%
(53 mmol/mol), especially early after di-
agnosis, can substantially reduce the
long-term complications that are charac-
teristic of diabetes (9–11). Third, clinical
studies have shown that antihypertensive
and lipid-lowering medications can re-
duce CVD in T2DM as effectively as they
do in the nondiabetic population (12) and
that CVD risk in diabetes is decreasing (13).
Finally, in the past two decades, the diabe-
tes epidemic has spurred the development
of eight new classes of glucose-lowering
medications that may allow for more effec-
tive control of glycemia in T2DMand, thus,
reduce complications (14).
One of the major challenges for prac-
titioners is to choose from the consider-
able armamentarium of glucose-lowering
medications the best means of maintain-
ing an appropriate level of glycemic con-
trol over time. Consensus algorithms
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have been developed to help clinicians to
select among the numerous medications
and their combinations for achieving and
maintaining a target A1C of ,7% (53
mmol/mol) (15–17). Other published al-
gorithms selected different glycemic goals
and recommended different strategies to
achieve them (18). Recent American Col-
lege of Physicians guidelines suggest that
metformin is the only drug supported by
solid evidence and that data are insuffi-
cient to choose a second agent (19). The
dearth of head-to-head comparator stud-
ies of glucose-lowering medications, ei-
ther alone or in combinations, and of
trials that have lasted .6–12 months to
examine the durable effects of interven-
tions on glycemic control (10,11,20,21)
has hampered the development of all
these algorithms.
Because T2DM is a progressive dis-
ease with worsening metabolic control
over time, the long-termglycemia-lowering
effects of interventions are particularly im-
portant. Safety, side effect profiles, toler-
ability, patient acceptance, burden of
therapy, and cost are other important factors
in the long-term treatment of this chronic,
degenerative disease. Finally, recent posi-
tion statements have emphasized individ-
ualization and patient-centered approaches
to therapy (15), but few studies have exam-
inewhich patientsmight do better orworse
with specific therapies.
Comparative effectiveness research
has been identified as a high national
priority in the U.S. (22). Similarly, im-
proved understanding of phenotypic
and genotypic differences between pa-
tients that affect responses to medications
has been identified as an important ele-
ment in individualizing therapy for max-
imum effectiveness (23). Of note, most
industry-sponsored studies have not ad-
dressed either long-term comparative ef-
fectiveness or interpatient differences that
may affect responses to therapy. As a re-
sult, patients with T2DM are currently
treated without taking into account indi-
vidual characteristics thatmight direct the
choice of more effective interventions.
The Glycemia Reduction Approaches
in Diabetes: A Comparative Effectiveness
Study (GRADE) is a pragmatic clinical
trial that will make head-to-head compar-
isons of major drug classes currently used
to treat T2DM, with the overarching goal
of providing better guidance to practi-
tioners in the choice of medications.
Specifically, GRADE will compare a sul-
fonylurea, dipeptidyl peptidase 4 (DPP-4)
inhibitor, glucagon-like peptide 1 (GLP-1)
receptor agonist, and basal insulin in pa-
tients with recently diagnosedT2DM treated
with metformin and will examine their
effectiveness in maintaining the glycemic
goal (A1C ,7% [53 mmol/mol]) over
time. Other outcomes will include relative
effects on selected microvascular compli-
cations and cardiovascular risk factors;
patient-centered outcomes, such as ad-
verse effects, acceptability, and tolerability;
and cost-effectiveness. Finally, GRADEwill
study the phenotypic characteristics that
underlie the success, failure, and adverse
effects of the different combinations to
guide individualized treatment.
GRADE DESIGN AND
METHODSdThe concept of a com-
parative effectiveness study examining
T2DM treatment was first presented to
the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK)
of the National Institutes of Health, by
D.M.N. in 2008. With provisional enthu-
siasm expressed by NIDDK and financial
support from the American Diabetes As-
sociation, clinical trialists D.M.N., J.B.B.,
Hertzel C. Gerstein, Rury R. Holman,
Richard Kahn, S.E.K., J.M.L., and Bernard
Zinman designed a preliminary proposal
in early 2009. A U34 planning grant (to
D.M.N., principal investigator) was funded
in August 2010, and during the ensuing
2 years, the authors of this article de-
veloped a final protocol (available on
the GRADE website at https://grade.bsc
.gwu.edu and in Supplementary Data).
A notice of opportunity was issued to so-
licit donations of medications within the
four classes and other supplies, and the
specific medications were selected by a
subgroup with no dualities of interest.
In addition, requests for applications
were issued to clinical centers, central lab-
oratories, and support units, which were
subsequently selected by peer review. Ad-
ditionally, study forms, model informed
consents, and a manual of operations
were developed.
GRADE was reviewed by an indepen-
dent external evaluation committee in
December 2011, reviewed and recom-
mended for funding by an NIDDK study
section in August 2012, and approved by
the NIDDK Advisory Council in Septem-
ber 2012. Funding of the study began in
October 2012 through a U01 grant (co-
principal investigators D.M.N. and J.M.L.)
to The George Washington University Bio-
statistics Center.
The data and safety monitoring board,
an independent review group appointed by
NIDDK, first convened on 1 February
2013. The GRADE steering committee,
comprising the principal investigators of
the clinical centers, representatives of the
NIDDK, and selectedmembers of the study
group approved the final study protocol in
March 2013. GRADE will begin recruit-
ment at 37 centers in mid-2013.
Major specific aims
The relative effects of four commonly
used glucose-lowering medications with
different mechanisms of action when
added to metformin will be compared
for the following:
c Maintenance of metabolic control, de-
fined as time to primary failure with an
A1C$7.0% (53mmol/mol), confirmed,
while receiving maximally tolerated
doses of both metformin up to 2,000
mg/day and the assigned medication;
c The time to secondarymetabolic failure
with an A1C .7.5% (58 mmol/mol),
confirmed, requiring the addition of
basal insulin for oral agent-treated
subjects and intensification of insulin
therapy for those assigned to basal in-
sulin at baseline;
c The time to tertiary metabolic failure
with an A1C .7.5% (58 mmol/mol),
confirmed, requiring implementation
of intensive insulin therapy with basal
plus rapid-acting insulin, while treated
with metformin, the assigned study
medication, and basal insulin among
those not originally assigned to basal
insulin;
c Cumulative incidence of diabetes com-
plications, such as microalbuminuria;
and
c Other metabolic outcomes, adverse ef-
fects, and effects on CVD risk factors,
quality of life, tolerability, and cost-
effectiveness.
In addition, we will determine the
phenotypic characteristics associated
with response to and failure of the four
different medication combinations and
identify factors that determine the success
and/or failure of specific regimens over
time, including longitudinal mechanistic
investigations of b-cell function.
Design
GRADEwill be a pragmatic, parallel-group,
clinical trial that compares as objectively
as possible the effects of four different
glucose-loweringmedications inmetformin-
treated patients with relatively recently
diagnosed T2DM. Subjects will adjust
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metformin during the run-in phase to
achieve maximum tolerated doses of
2,000 mg/day with at least 1,000 mg/day
required for eligibility (Fig. 1). The trial is
unmasked for practical reasons because it
will compare oral agents and injectable
medications.
Eligible subjects will be randomly
assigned to one of the four medications
shown in Fig. 1. The principal compari-
sons among these medications will start
from the time of randomization. The trial
will be conducted under an intention-to-
treat design. All randomized subjects will
continue follow-up and complete all out-
come assessments until the planned con-
clusion of the study (planned follow-up of
4–7 years, depending on the time of en-
try), including those who reach the pri-
mary outcome. Otherwise, analyses of all
other outcomes would be susceptible to a
healthy survivor effect because the only
subjects evaluated in the out years would
be those who had not yet experienced pri-
mary failure of the assigned regimen. To
encourage retention in the study over
time and ensure a longer exposure to
the study medications for the purposes
of analyses of other outcomes, assigned
study medications will be continued until
the need for intensification of insulin
therapy with basal plus rapid-acting insu-
lin (Fig. 2).
GRADE was designed entirely by the
planning group (the authors) with input
from an NIDDK-appointed external eval-
uation committee and the investigators.
No pharmaceutical manufacturers con-
tributed to the planning or design or will
participate in the conduct of GRADE.
Medication and supply manufacturers
were approached to donate product after
the medications and supplies had been
selected by members of the planning
group without any dualities of interest.
Study population and recruitment
GRADE will compare the relative effects
of the four interventions in relatively
recently diagnosed T2DM subjects treated
with metformin, with the recognition
that earlier treatment is more likely to
maintain endogenous insulin secretion
and promote advantageous levels of gly-
cemia over time (24). Eligibility criteria
enumerated in the protocol (Supplemen-
tary Data) and summarized in Table 1
reflect a balance between the stringent re-
quirements usually applied in recruiting a
clinical trial population and the desire to
create a pragmatic and easily translatable
study.
To be eligible, potential subjects must
have an A1C of 6.8–8.5% (51–69 mmol/
mol), as measured in the central labora-
tory, after metformin therapy has been
maximized, as tolerated, during the run-
in period. The study cohort (Fig. 1) of
5,000 subjects will include patients with
,5 years’diabetes durationwho are treated
with metformin but no other glucose-
lowering medications. The majority of
potential subjects will be identified on
the basis of a prior diagnosis of diabetes
detected through reviews of medical his-
tories and self-reports and aided by the
use of electronic medical records and
other databases.
GRADE will aim to recruit as much
representation as possible from racial and
ethnic minority groups that are dispro-
portionately affected by T2DM and a sub-
stantial fraction (.20%) who are $60
years of age. Recruitment and implemen-
tation of the GRADE protocol will take
place at 37 clinical centers, which were
selected by peer review through an open
competition process. The GRADE clinical
centers (Supplementary Data) are distrib-
uted throughout the U.S. (Supplementary
Data) and were selected in part because of
their ability to recruit a diverse population
of research subjects, including patients
.60 years of age. Each clinical center
will enroll 150 eligible subjects to reach
the study-wide total enrollment of 5,000
subjects over a period of ;3 years.
Interventions
Rationale. Metformin was selected as the
foundation therapy according to the same
rationale used in most of the recently
developed consensus algorithms (15–
18), namely, its long-term clinical experi-
ence, effectiveness in lowering glycemia
over a wide range of A1C levels without
causing hypoglycemia, weight-neutral or
weight-loss effect, putative cardiovascular
risk reduction (10,11,25), safety and side
effect profiles, high level of patient toler-
ance, and low cost. Recent surveys have
shown that a large majority of patients
with recent-onset T2DM are treated with
metformin (26), making this choice both
practical and clinically relevant.
The selection of the other study med-
ications from the ten classes of available
agents to add to metformin was predi-
cated on the most commonly used ap-
proved combinations and the availability
of preliminary data to support their gly-
cemia-lowering effectiveness, safety, and
tolerability. Increasing concern about the
future of pioglitazone, owing to the pu-
tative increased risk for bladder cancer
(27) superimposed on previously estab-
lished safety concerns regarding volume
retention and bone loss, contributed to its
elimination from the study design. The
potential adverse impact on recruitment
of including a drug that is receiving in-
creasing and highly visible negativeFigure 1dStudy design.
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attention was an additional consider-
ation. Because the four medication classes
proposed capture the majority of glucose-
lowering medications prescribed, and all
four combinations have been approved
by the Food and Drug Administration
and its European and Canadian counter-
parts, the study will be clinically relevant
and generalizable, and its results immedi-
ately and widely translatable to practice.
Medications. We selected specific agents
within the four classes as dictated by their
specific attributes. All have been studied
(28–31) and are approved by the Food
and Drug Administration in their pro-
posed initial combinations. The criteria
by which specific agents were chosen
within classes by members of the plan-
ning group without any dualities of inter-
est included differences between the
agents in the following: lowering glyce-
mia, published side effect profiles, effects
on CVD risk factors, clinical experience,
ease of administration, and acceptability.
In cases where there were no appreciable
or substantive differences between agents
within the classes, consideration was
given to those agents that are used most
frequently and weremade available by the
manufacturers. At the time of randomiza-
tion, all subjects will be assigned to one of
the following medications in each of the
named classes: sulfonylurea (glimepir-
ide), DPP-4 inhibitor (sitagliptin), GLP-1
receptor agonist (liraglutide), or insulin
(glargine) (Fig. 2).
The number of medications selected
in GRADE was predicated on resource
availability. The other classes of glucose-
lowering medications, aside from piogli-
tazone (discussed previously), that were
considered but not chosen were the
a-glucosidase inhibitors, nonsulfony-
lurea sulfonylurea receptor agonists,
rapid-acting insulins, bile acid seques-
trant colesevelam, and dopamine agonist
bromocriptine. They were not selected
for a number of reasons, including poten-
tial safety concerns, limited clinical use
and experience in recent-onset T2DM,
and relatively low efficacy, poor tolerabil-
ity, and frequent side effects. No agents in
the most recent class of glucose-lowering
medications, the SGLT-2 inhibitors, had
been approved during the planning phase
of GRADE. Moreover, none of them had
sufficient clinical use or experience to be
acceptable in the study.
Diabetes management strategy. All the
medications will be used according to
their labeling and/or usual practice (32).
Adjustments of glimepiride or insulin will
be based on self-monitoring of blood glu-
cose, aiming for fasting glucose levels
between 70 and 130 mg/dL without symp-
tomatic hypoglycemia. Additionally, med-
ications will be titrated to achieve A1C
values ,7.0% (53 mmol/mol) up to the
maximally tolerated dose (Table 2).
GRADE staff at each clinical center
will assume responsibility for glycemic
management of subjects according to the
GRADE protocol and will communicate
this arrangement with the primary-care
providers. Of note, GRADE staff will not
be responsible for routine surveillance for
diabetes complications or for the treat-
ment of other cardiovascular risk factors;
however, the results of clinically relevant
physical examination and laboratory re-
sultswill be communicated to subjects’ care
providers to aid clinical management.
The randomly assigned medication
andmetforminwill be continued until the
secondarymetabolic outcome (see OUTCOMES)
has been reached (Fig. 2), at which time
basal insulin (glargine) will be added for
the three groups that were not originally
assigned to insulin, using the same algo-
rithm as in the original glargine-assigned
treatment group. The rationale for the
continued combination therapy is to
maximize the time while receiving the as-
signed treatment and to enable further
study of which combinations may delay
further metabolic worsening to the need
for insulin intensificationdthe tertiary
metabolic outcome. Moreover, the use
of three agents has become increasingly
popular in routine clinical practice.
For the group that was originally
assigned to glargine, insulin intensifica-
tion with rapid-acting (aspart) insulin will
be started and adjusted by GRADE clinic
staff according to the study protocol after
the secondary metabolic outcome has been
reached (Fig. 2). In the three groups origi-
nally assigned to treatment other than glar-
gine, intensification of insulin therapy with
rapid-acting insulin will be implemented
when the tertiary metabolic outcome is
reached. Their randomly assigned medica-
tion will be stopped at that time.
Self-monitoring of blood glucose. Sub-
jects assigned to insulin or sulfonylurea
for safety reasons (to prevent hypoglyce-
mia) will self-monitor blood glucose lev-
els on a specified schedule and adjust
doses to achieve glucose goals according
to usual care recommendations (32). Self-
monitoring of blood glucose levels will
also be recommended for safety reasons
for all subjects with symptoms suggestive
of hypoglycemia or hyperglycemia or
during intercurrent illness likely to affect
glucose control.
Outcomes
Metabolic outcomes. The primary out-
come is the time to primary metabolic
failure of the randomly assigned treatment,
which is defined as the time to an initial
A1C $7% (53 mmol/mol), subsequently
confirmed at the next quarterly visit, while
Figure 2dMetabolic outcomes and subsequent therapy.
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being treated at maximum tolerable doses
of both metformin and the second ran-
domly assigned medication. If the second
(confirmatory) A1C is ,7% (53 mmol/
mol), then the primary outcome is not yet
reached.
If the initially observed A1C is .9%
(75 mmol/mol), then confirmation will
be performed within 3–6 weeks. Taking
into account the need for confirmation,
the earliest time that the primary end
point can be confirmed is at 6 months
after randomization for subjects whose
A1C at 3 months is$7% and at 4 months
if the 3-month A1C is .9%. All A1C
resultswill bemeasured in the study central
laboratory.
The secondary outcome is the time to
the observation of an A1C .7.5% (58
mmol/mol), subsequently confirmed,
while treated with originally assigned
medications andmetformin. For the three
groups originally assigned to medications
other than insulin, the tertiary outcome is
the time to an A1C .7.5% (58 mmol/
mol), confirmed as previously described,
while receiving metformin, the originally
assigned medication, and basal insulin.
Each of the three metabolic outcomes
will be counted regardless of adherence
to assigned medications, according to
the principles of intention-to-treat analysis.
Other outcomes. A full list of the GRADE
outcomes is included in the protocol
(Supplementary Data). They can be con-
sidered in the following categories: meta-
bolic, such as mean A1C and fasting
plasma glucose levels, frequency of hypo-
glycemia, and measures of insulin secre-
tion and sensitivity; cardiovascular,
including risk factors and major events;
microvascular, such as albuminuria, esti-
mated glomerular filtration rate (eGFR),
and peripheral neuropathy; adverse
events specific to the medications under
study; adverse effects; adherence and tol-
erability to metformin and the assigned
medications and treatment satisfaction;
health economics; and other outcomes,
including mortality, hospital admissions,
cognitive function, and cancer.
Baseline and follow-up measure-
ments of phenotypic variables (demo-
graphic, physiologic, and genetic) will
facilitate the study of patient factors that
may mediate responsiveness to different
therapies. Oral glucose tolerance testing,
performed annually, will contribute to
our understanding of the mechanisms of
medication success and failure. From
these assessments, a number of different
outcome measurements will be obtained
with the goal of assessing the differential
metabolic effects of each drug combina-
tion on b-cell function and insulin sen-
sitivity over time. These measurements,
combined with the phenotypic measures,
will be used to determine patient-specific
characteristics that are associated with
responsiveness or failure to respond to spe-
cific agents and will facilitate an under-
standing of how to individualize therapy.
Statistical analyses and power
calculations
All analyses will compare the randomly
assigned treatment groups under the in-
tention-to-treat principle with use of the
treatment as assigned to each subject and
all available data from all subjects.
Primary outcome. The cumulative in-
cidence of the primary outcome within
each treatment group will be estimated
with amodified, discrete-timeKaplan-Meier
estimate, allowing for periodic outcome
assessments (33). Differences between
groups will be tested and relative risk es-
timates obtained from a Cox proportional
hazards model for discrete time observa-
tions adjusted for the baseline A1C (33).
A single overall omnibus test at the 0.05
significance level will be conducted as well
Table 1dSummary of major eligibility criteria*
Inclusion criteria
1. Men or women$30 years of age at time of diabetes diagnosis; for American Indians, $20
years of age at time of diagnosis
2. Duration of diagnosed diabetes,5 years determined as accurately as possible on the basis of
available records at screening
3. A1C criteria (at final run-in visit,;2weeks before randomization): 6.8–8.5% (51–69mmol/
mol)
4. Taking a daily dose of $1,000 mg metformin for a minimum of 8 weeks at final run-in
5. Willingness to administer daily subcutaneous injections, take a second diabetes drug after
randomization, potentially initiate insulin, intensify insulin therapy if study metabolic goals
are not met, and perform self-monitoring of blood glucose
6. A negative pregnancy test for all women of childbearing potential (i.e., premenopausal, not
surgically sterile)
7. Provision of signed and dated informed consent before any study procedures
Exclusion criteria
1. Suspected type 1 diabetes (lean with polyuria, polydipsia, and weight loss with little
response to metformin) or secondary diabetes resulting from specific causes (e.g.,
previously diagnosed monogenic syndromes, pancreatic surgery, pancreatitis)
2. Current or previous (within past 6 months) treatment with any diabetes drug or glucose-
lowering medication other than metformin, including short-term insulin use during
hospitalization
3. More than 5 years of treatment with metformin at time of randomization
4. History of intolerance, allergy, or other contraindications to any of the proposed study
medications
5. A life-threatening event within 30 days before screening or currently plannedmajor surgery
6. Anymajor cardiovascular event in previous year, including history of myocardial infarction,
stroke, or vascular procedure, such as coronary artery or peripheral bypass grafting, stent
placement (peripheral or coronary), or angioplasty
7. Plans for pregnancy during the course of the study for women of childbearing potential
8. History of or planning for bariatric surgery, including banding procedures or surgical gastric
and/or intestinal bypass
9. History of congestive heart failure (New York Heart Association class III or IV)
10. History of conditions that are specific contraindications to any of the study medications
11. Serum creatinine level$1.4 mg/dL in women and$1.5 mg/dL in men or end-stage renal
disease requiring renal replacement therapy
12. History of cancer, other than nonmelanoma skin cancer, that required therapy in the 5
years before randomization
13. Treatment with oral or systemic glucocorticoids (other than short-term treatment, e.g., for
poison ivy) or disease likely to require periodic or regular glucocorticoid therapy (inhaled
steroids allowed)
14. Treatment with atypical antipsychotics
15. Clinically or medically unstable with expected survival ,1 year
*A complete list of the eligibility criteria is included in the protocol (Supplementary Data).
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as significance tests and relative risk (haz-
ard ratio) estimates for each of the six
pairwise drug group comparisons, with
P values adjusted with the Holm closed
sequential multiple testing procedure
(34). If tests of the proportional hazards
assumption do not apply, inferences (CIs
and P values) will be obtained from ro-
bust information sandwich estimates of
SEs (35).
Other outcomes. Similar analyses will be
applied to other secondary discrete time-
to-event outcomes, such as the time to
secondary metabolic failure or to micro-
albuminuria based on 6-monthly albu-
min: creatinine ratio measurements. For
time-to event outcomes measured nearly
continuously, such as the number of days
to a cardiovascular event, this strategy will
use the corresponding methods for con-
tinuous time observations.
For longitudinal analyses of binary
outcomes over time, such as the propor-
tion of subjects (prevalence) at each visit
who are still maintaining an A1C ,7%
while receiving the originally assigned
therapy, the odds will be compared
between groups with use of a repeated-
measures logistic model fit through gen-
eralized estimating equations with a
robust estimate of the covariance struc-
ture (34). Longitudinal analyses of quan-
titative outcomes over time (e.g., A1C)
will use a longitudinal normal errors
repeated-measures model for the estima-
tion of group mean levels over time (36).
For longitudinal assessments of the rate of
change of an outcome over time, such as
the slope of the decline in eGFR, a random-
effects (random coefficient) model will be
used to estimate the mean slope within
each treatment group, allowing for ran-
dom variation of slopes among subjects
(36). Comparison of rates of events (e.g.,
hypoglycemia) will use Poisson regres-
sion models with the robust information
sandwich variance estimates (33).
Composite outcomes. A multivariate
one-sided (or one-directional) test of sto-
chastic ordering will be conducted to
compare differences between groups for
multiple outcomes simultaneously, such
as A1C, weight, and hypoglycemia. The
O’Brien mean rank score test (37) will be
applied to an analysis of multiple quanti-
tative (or ordinal) components at a single
point in time. The Wei-Lachin test of sto-
chastic ordering will be used to test other
components, including proportions, rates,
and event times (38). In addition, a single
composite outcome can be defined from
the components, such as the prevalence
of subjects at 4 years who are still able to
maintain an A1C,7% without having ex-
perienced severe hypoglycemia or gained
weight. A longitudinal analysis of the pro-
portions meeting this criterion at each visit
over time and a survival analysis of such
outcomes will also be conducted. Propor-
tional hazards and parametric regression
models will be used to assess the ability of
multiple variables simultaneously to pre-
dict the time to primary or to secondary
failure.
Subgroup and stratified analyses. Anal-
yses will also assess the differences in study
outcomes within subgroups defined by
baseline characteristics, including race/
ethnicity, sex, age, diabetes duration,
weight, body mass index, A1C, and mea-
sures of insulin sensitivity, insulin secre-
tion, and the glucose disposal index. For
each factor, the treatment groups will be
compared separately within each subgroup
(e.g., males, females) with a test of homo-
geneity between strata. For a quantitative
variable (e.g., age), an additional analysis
will be conducted with use of the quanti-
tative covariate rather than simply of the
discrete strata.
Sample size and power
With recruitment over 3 years and total
study duration of 7 years, continued
follow-up of all subjects to study end
would provide 4–7 years of follow-up. To
be conservative, sample size and power
for the primary analysis were computed
assuming a lag in recruitment, with 40%
of subjects recruited in the first half of the
3-year recruitment period (39). Assuming
that 4% will be lost to follow-up before
reaching the primary outcome, the aver-
age follow-up time would be 4.8 years,
with 15% of subjects lost to follow-up.
Primary outcome. On the basis of the
ADOPT (ADiabetesOutcomes Progression
Trial) (20), we conservatively estimated a
hazard rate of 0.0875 per year for the pri-
mary outcome. With the aforementioned
assumptions, a sample size of 1,242 per
group (rounded to 1,250) provides 90%
power to detect a 25% risk difference at a
significance level of 0.00833, adjusting for
six pairwise tests.
Secondary outcomesdmicroalbuminuria
and clinical CVD. The hazard rate of
onset of microalbuminuria is projected to
be ;0.04 per year in whichever group
has a higher event rate (40). The 5,000
subjects provide 88% power with a haz-
ard rate of 0.04 per year, or 92% with
0.045 per year, to detect a 33% difference
in risk for microalbuminuria between any
pair of groups.
In the ADOPT study (20), the inci-
dence of major atherosclerotic cardiovas-
cular events was 0.76% per year and of
major atherosclerotic cardiovascular events
plus congestive heart failure, 1.14% per
year. Assuming an incidence rate of 1%
per year, GRADE will provide 80% power
to detect a 50% difference in the risk of
CVD between any pair of drug groups, ad-
justed for six pairwise comparisons.
CONCLUSIONSdGRADE is a com-
parative effectiveness study that aims to
compare four major classes of glucose-
lowering medications in relatively re-
cently diagnosed T2DM patients treated
with metformin. The study is unique in
comparing as many major diabetes treat-
ments as possible, given available study
resources, over a clinically relevant pe-
riod. GRADE is also unique because it will
study the totality of the effects of the
medications, including an emphasis on
patient-centered outcomes in addition to
metabolic outcomes. Finally, its focus on
individual demographic, clinical, and
other factors that may influence a differ-
ential response to medications will add to
our understanding of therapy for T2DM.
GRADE results should not only help
practitioners to choose the medications
Table 2dInitiation and adjustment of assigned study medications
Medication Initial dose Adjustment
Glimepiride A1C #8% 1 mg,
.8% 2 mg
Weekly adjustment based on self-monitoring of
blood glucose level to a maximum of 4 mg
twice daily
Sitagliptin 100 mg/day Reduce to 50 mg if eGFR ,45 mL/min
Reduce to 25 mg if eGFR ,30 mL/min
Liraglutide 0.6 mg/day Advance to 1.2 mg and then 1.8 mg, as tolerated
Glargine 10 units Increase or decrease dose according to
self-monitoring of blood glucose level and
hypoglycemia
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that are the most appropriate with regard
to metabolic control and patient-oriented
outcomes, but should also provide insights
to allow individualization of treatment.
The major aims of GRADE, which
focus on a comparison of the effectiveness
and other clinically important attributes
of glucose-lowering medications, have
major health economic implications in
addition to their obvious public health im-
pact. The cost of glucose-lowering medi-
cations accounts for a disproportionate
share of medication costs, doubling from
6.3% of all prescribed drug spending in the
U.S. in 2001 to 12.2% in 2007 (5).
The planning process for GRADE
differed from that for most large, multi-
center trials sponsored by NIDDK. The
U34 planning grant was used to allow a
relatively small group of investigators to
plan, design, and develop the study to the
point of implementation. This process
contrasts with the usual design of multi-
center trials by a large group of investiga-
tors who have been selected on the basis of
their response to a request for application.
GRADE investigators will leverage the
core study to amplify the range of scien-
tific inquiry by actively promoting ancil-
lary studies. These independently funded
projects will take advantage of the study
design and cohort. Some, such as genetics
studies, will require minimal subject par-
ticipation, whereas others may involve
additional study procedures; however, all
ancillary proposals will be judged on the
basis of clinical and scientific value and
burden to the subjects and centers.
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